id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-261370-jp5sqqwc	Bollag, Wendy B.	Phosphatidylglycerol and Surfactant: A Potential Treatment for COVID-19?	2020-09-16		.txt	text/plain	4096	177	33	It is thought that surfactant, which is already approved by the Food and Drug Administration for intratracheal administration to treat neonatal respiratory distress syndrome in infants, could benefit COVID-19-infected individuals by: (1) restoring surfactant damaged by lung infection and/or decreased due to the virus-induced death of the type II pneumocytes that produce it and (2) reducing surface tension to decrease the work of breathing and limit pulmonary edema. In addition, a constituent of surfactant, phosphatidylglycerol, could mitigate COVID-19-induced lung pathology by: (3) decreasing excessive innate immune system activation via its inhibition of toll-like receptor-2 and -4 activation by microbial components and cellular proteins released by damaged cells, thereby limiting inflammation and the resultant pulmonary edema, and (4) possibly blocking spread of the viral infection to non-infected cells in the lung.	./cache/cord-261370-jp5sqqwc.txt	./txt/cord-261370-jp5sqqwc.txt